Product Pipeline

Developing drugs for drug-resistant, life threatening infections.

Product Candidates

The next generation of anti-infectives.

We plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. Our most advanced product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia and CF-404, a cocktail of monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza.

Program Research Candidate Section IND-Enabling Phase 1 Phase 2
Lysin Candidates
CF-301* – S. aureus - Complicated Bacteremia
Research Phase complete
Candidate Section Phase complete
IND-Enabling Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
CF-303 – S. pneumoniae
Research Phase in progress
Candidate Section Phase not started
IND-Enabling Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
CF-304 – S. faecalis and E. faecium
Research Phase in progress
Candidate Section Phase not started
IND-Enabling Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
CF-305 – S. agalactiae
Research Phase in progress
Candidate Section Phase not started
IND-Enabling Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
CF-306 – B. anthracis
Research Phase in progress
Candidate Section Phase not started
IND-Enabling Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
CF-307 – Group B Streptococcus
Research Phase in progress
Candidate Section Phase not started
IND-Enabling Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
Antibody Candidates
CF-404 – Seasonal and Pandemic Influenza
Research Phase complete
Candidate Section Phase complete
IND-Enabling Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
  • *CF-301 has been granted Fast Track Designation from the FDA for the treatment of Staph aureus bacteremia.

Product Candidates

Market Need

Drug resistance is a global crisis

2 Million

Illnesses Diagnosed in the U.S.

700,000

Deaths, Worldwide

MRSA

A bigger killer than HIV/AIDS, Parkinson's Disease, emphysema and homicide, in the U.S.

64%

Likelihood of death among individuals with MRSA Versus those infected with MSSA

Projection

Projected Annual Worldwide Statistics in 2050

10 Million

Deaths Annually

$100 Trillion

Costs By 2050

About

Our Technology

Our platform enables the production of lysin banks specific for any particular bacterial pathogen

Learn More »
About

Contrafect Corporation

We focus on developing protein and antibody therapeutic products.

Learn More »